Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
The Tryptophan Paradox: From Microbiome-Mediated Homeostasis to Tumor-Driven Immune Escape.
Journal: International journal of molecular sciences
Published: April 08, 2026
Impact of frailty on outcomes of inpatient stereotactic radiosurgery for brain metastasis: a national readmission database analysis 2016-2020.
Journal: Radiation oncology (London, England)
Published: May 22, 2025
A platform of ADAPTive scaffolds: development of CDR-H3 β-hairpin mimics into covalent inhibitors of the PD1/PDL1 immune checkpoint.
Journal: RSC chemical biology
Published: July 24, 2024
Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer.
Journal: Cancer & metabolism
Published: October 17, 2022
Exploiting the Innate Plasticity of the Programmed Cell Death-1 (PD1) Receptor to Design Pembrolizumab H3 Loop Mimics.
Journal: Chembiochem : a European journal of chemical biology
Published: August 03, 2022
Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma.
Journal: International journal of molecular sciences
Published: June 23, 2021
Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration.
Journal: International journal of molecular sciences
Published: June 08, 2021
Targeting the Proline-Glutamine-Asparagine-Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 28, 2020
Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors.
Journal: Translational oncology
Published: June 03, 2019
Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer.
Journal: Molecular cancer research : MCR
Published: March 06, 2019
Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
Journal: Cancer
Published: February 18, 2019
Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report.
Journal: Medicine
Published: January 12, 2019
Last Updated: 09/26/2026